Aarti Drugs Share Price

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. In addition, it offers pharma intermediate products, an develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. Aarti Drugs share price on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

The Aarti Drugs stock price is influenced by various factors such as API pricing trends, raw material costs, regulatory approvals from bodies like the USFDA, and global export demand. Over the longer term, strategies including capacity expansion, backward integration, and diversification into high-value segments affect investor sentiment. All these factors must be closely monitored to have an idea about the Aarti Drugs stock price movements.

Aarti Drugs live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant ͏monitoring of Aarti Drugs live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Aarti Drugs share͏ price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Aarti Drugs Limited Company Fundamentals

Aarti Drugs Limited Company Background

Founded in 1984, Aarti Drugs Ltd. is a part of the Aarti Group of Industries, a diversified group with a global presence. The company operates with a strong focus on research and development, supported by its R&D centre at Tarapur in the Maharashtra Industrial Development Corporation (MIDC). This location allows close coordination between research activities and manufacturing operations. Aarti Drugs is engaged in the production of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, and Specialty Chemicals, serving a wide range of pharmaceutical requirements. Its formulations business is managed through its wholly owned subsidiary, Pinnacle Life Science Private Limited. International marketing and distribution are carried out through overseas subsidiaries, Pinnacle Chile SpA in Chile and PharmaGo SpA, enabling the company to cater to global markets with consistency and compliance. Guided by scientific understanding and a long-term approach to growth, Aarti Drugs continues to build on decades of experience while adapting to the evolving needs of the pharmaceutical industry.

Aarti Drugs Limited Company Product Lines

Active Pharmaceutical Ingredients (APIs): Aarti Drugs manufactures a diverse portfolio of APIs across multiple therapeutic categories, including:

• Antibiotics (e.g., Ciprofloxacin Hydrochloride, Ofloxacin, Levofloxacin, Norfloxacin and other fluoroquinolones)
• Antiprotozoals (e.g., Metronidazole, Tinidazole, Metronidazole Benzoate)
• Antidiabetics (e.g., Metformin Hydrochloride)
• Antifungals (e.g., Ketoconazole)
• Anti-inflammatory and analgesic APIs (e.g., Nimesulide)
• Cardioprotective and other categories of pharmaceutical actives

Pharma Intermediates: Intermediate chemicals that are used as precursors in the synthesis of APIs, supporting both internal manufacturing and third-party API development.

Specialty Chemicals: Includes a range of fine and specialty chemicals such as:

• Benzene Sulphonyl Chloride
• Methyl Nicotinate
• Other chlorosulphonation derivatives and specialty building blocks

Formulations (Through Subsidiary): Finished pharmaceutical products (formulations) are manufactured by the wholly-owned subsidiary Pinnacle Life Science Private Limited. These cover selected therapeutic categories and are marketed globally.

Products Under Development: This pipeline reflects new products Aarti Drugs Ltd. is developing to expand its therapeutic coverage:

• Antifungal: Itraconazole
• Cardiovascular: Ticagrelor
• Antidiabetic: Sitagliptin
• NSAIDs (Non-steroidal anti-inflammatory drugs): Aspirin

Aarti Drugs LImited Company Revenue Model

Aarti Drugs’ revenue is generated through multiple streams:

• Sales of APIs: Largest contributor, supplying bulk pharmaceutical actives to drug manufacturers globally, including antibiotics, antidiabetics, antifungals, anti-inflammatories, and cardiovascular APIs.
• Specialty Chemicals & Intermediates: Revenue from sales of specialty chemical products used in pharmaceuticals and other industrial applications.
• Formulations: Finished dosage formulations marketed through Pinnacle Life Science. This segment contributes a portion of overall revenue.
• Exports: A significant share of revenue comes from export markets, with products shipped to over 100 countries including North America, Europe, Latin America, Africa, and Asia.
• Contract Manufacturing & Custom Synthesis: Offers API contract manufacturing and custom synthesis to partners, tailored to specific requirements

Aarti Drugs Limited Geographic Presence

• Aarti Drugs exports APIs, specialty chemicals, and intermediates to more than 100 countries worldwide across multiple regions, including:
• North America
• Europe
• Latin America
• Africa
• Asia

Manufacturing Footprint in India:

• The company operates multiple manufacturing facilities across India, primarily in:
• Maharashtra (major API, intermediates and specialty chemical plants)
• Gujarat (manufacturing units compliant with global standards)
• Himachal Pradesh (formulation facility via subsidiary)

Regulatory & Compliance Reach:

• Facilities adhere to international standards (US FDA, WHO-GMP) and serve both regulated and semi-regulated markets.

Overseas Marketing & Distribution:

• Products are also marketed through international subsidiaries and logistics partnerships, including entities such as Pinnacle Chile SpA and PharmaGo SpA for wider global reach

Aarti Drugs Limited Leadership 

Some of the key leaders of Aarti Drugs Limited as of January 2026 are

• Chandrakant V. Gogri – Chairman Emeritus & Chief Executive Officer
• Prakash M. Patil – Chairman, Managing Director & Chief Executive Officer
• Rashesh C. Gogri – Managing Director
• Harshit M. Savla – Joint Managing Director
• Harit P. Shah – Executive Director
• Uday M. Patil – Executive Director
• Narendra J. Salvi – Non-Executive Director
• Adhish P. Patil – Chief Financial Officer & Chief Operating Officer
• Ankit V. Paleja – Independent Director
• Bhaskar N. Thorat – Independent Director
• Neha R. Gada – Independent Director
• Hasmukh B. Dedhia – Independent Director
• Sandeep M. Joshi – Independent Director
• Ajit E. Venugopalan – Independent Director

Aarti Drugs Limited Key Milestones

• 1984: Aarti Drugs Limited (ADL) incorporated in September as a manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals under the Aarti Group.
• 1993: Implemented the second phase of backward integration and set up facilities for glyoxal, a key raw material for imidazoles.
• 1994–95: Commissioned a plant to recover and market ammonium sulphate from plant effluents; amalgamation of Rupal Chemical Industries with the Company.
• 1996–97: Commenced production of Secnidazole and Diclofenac Sodium.
• 2000–01: Started commercial production of pharmaceutical ingredients.
• 2002–03: Expanded bulk drug production capacity by 598,000 kg, reaching 17,430,000 kg.
• 2003–04: Further increased bulk drug capacity by 588,000 kg to 18,018,000 kg.
• 2004–05: Began commercial production at the newly established intermediate plant at Tarapur.
• 2005–06:
  • Increased pharmaceutical production capacity by 2,325,000 kg to 24,020,000 kg.
  • Entered into a joint venture in China to form Huanggang Yinhe Aarti Pharmaceutical Company Ltd for API manufacturing and sales.
  • Acquired a controlling stake in Suyash Laboratories Ltd, making it a subsidiary.
• 2006–07: Expanded production capacity by 570,000 kg to 24,590,000 kg.
• 2007–08: Increased production capacity by 399,000 kg to 24,989,000 kg.
• 2008–09: Further expanded pharmaceutical production capacity to 25,000,000 kg.
• 2009–10:
  • Undertook process improvements in antihistaminic/anti-allergic, anti-inflammatory, and anti-diabetic bulk drugs.
  • Expanded total production capacity to 25,716,000 kg.
• 2012: Scheme of Amalgamation of Suyash Laboratories Ltd. with the Company became effective from 6 July 2012.
• 2015: Acquired 100% equity stake in Pinnacle Life Science Private Limited, Baddi, Himachal Pradesh, strengthening formulation capabilities.
• 2020:
  • Incorporated overseas subsidiary Pinnacle Chile SpA for formulation marketing and participation in Chilean tender and private markets.
  • Incorporated Aarti Speciality Chemicals Limited as a wholly owned subsidiary for specialty chemical operations.
• 2022: Commissioned brownfield expansion of the Specialty Chemicals plant at Tarapur; operations commenced in May 2022.
• 2024–25: First dermatology-focused project at the Tarapur facility commenced operations.

 Industry Perspective

Aarti Drugs Limited operates within the Active Pharmaceutical Ingredients (API), pharma intermediates, and specialty chemicals segment of the global pharmaceutical industry. APIs are the biologically active components in medicines and form the backbone of drug manufacturing worldwide. In 2024, the global API market was valued at around USD 209.8 billion and is projected to expand to approximately USD 445.7 billion by 2035, growing at a CAGR of about 7.15 % between 2025 and 2035. In India, the API industry was valued at about INR 1.07 trillion (~USD 13–14 billion) in 2023 and is expected to reach around INR 1.82 trillion by 2030, with a CAGR of roughly 8.26 % over 2025–2030. India is a major global supplier, exporting roughly 50 % of its APIs to regulated markets such as the United States and Europe.Growth is driven by rising demand for generic medicines, chronic disease treatments, aging populations, and diversification of global supply chains. Regulatory emphasis on GMP compliance and supportive policies further strengthen India’s and the global API sector’s future growth outlook.

Aarti Drugs Limited is well positioned to benefit from the expanding global API and pharmaceutical manufacturing industry. Rising demand for generic medicines, increasing chronic disease prevalence, and supply chain diversification away from single-country dependence support sustained API demand. Its diversified product portfolio, GMP-certified facilities, strong R&D capabilities, and growing presence in regulated export markets enable the company to capture long-term growth opportunities.

Aarti Drugs Limited Stock Market Presence: Listings & Index Representation

Aarti Drugs Limited is a recognized entity in the Indian stock market, listed with the symbol AARTIDRUGS on the NSE and the scrip code 524348 on the BSE.

Aarti Drugs holds representation across several market indices, underscoring its position within the pharmaceutical and broader market ecosystem. Its index memberships include the S&P BSE Healthcare, S&P BSE AllCap, S&P BSE 500, S&P BSE 250 SmallCap Index, S&P BSE 400 MidSmallCap Index, BSE 1000, S&P BSE MidSmallCap, S&P BSE SmallCap, BSE Next 250 Microcap, Nifty Microcap 250 Index, and Nifty Total Market.

The Aarti Drugs share price is monitored by investors seeking exposure to the API manufacturing sector. Its inclusion in these indices reflects its specific market capitalisation tier and operational focus on the pharmaceutical supply chain. Listing on both major exchanges ensures liquidity, while its presence across multiple indices connects it to various thematic and broad-based investment flows.

Aarti Drugs Limited Stock Performance and Share Price History

The Aarti Drugs share price reflects its standing as a focused API manufacturer. Its performance is driven by export realizations, domestic formulation demand, cost efficiency, and regulatory compliance. Investors often compare the Aarti Drugs share price today with sectoral indices and peers to gauge relative performance.

Operational results directly influence market movements. For instance, the Aarti Drugs share price surged 379.83% in 2020, primarily driven by increased demand for antibiotics and other APIs during the global pandemic. Conversely, the Aarti Drugs stock price declined 25.86% in 2021 and 15.35% in 2022 as pandemic-led demand normalized and input cost pressures escalated. Sector-wide challenges like pricing pressure in key export markets also played a role.

Corporate actions can impact short-term price movements. The Aarti Drugs share price history shows periods of volatility around earnings announcements and industry-wide developments. While such events cause near-term swings, the fundamental drivers of capacity utilization and product mix remain critical for the Aarti Drugs stock price over longer periods.

Longer-term trends are contextualized by the Aarti Drugs share price 52-week high and low. The 52-week high of ₹564.05 and low of ₹312 illustrate the stock’s trading range over the past year, capturing the effects of earnings cycles, sector rotation, and broader market sentiment. These levels provide a reference point for the stock’s recent performance history.

The Aarti Drugs stock performance reflects the dynamics of a pharmaceutical intermediate company. The company’s integrated operations, focus on key therapeutic areas, and export orientation have shaped its Aarti Drugs share price history. Over extended periods, the stock has experienced phases of significant growth and consolidation.

The early 2010s witnessed strong growth, with the Aarti Drugs share price increasing 193.29% in 2012 and 291.28% in 2014, driven by robust earnings expansion and favorable industry conditions. The Aarti Drugs stock price faced a correction of 48.20% in 2011 amid broader market weakness. A strong recovery followed, with gains of 38.09% in 2015.

More recently, the Aarti Drugs share price has seen periods of moderation. After the exceptional rise in 2020, the Aarti Drugs stock price underwent corrections in 2021 and 2022. The Aarti Drugs share price decreased 6.89% in 2024 and 9.41% in 2025, reflecting ongoing sectoral headwinds and margin pressures. In 2023, the Aarti Drugs share price gained 8.12%, supported by improved operational performance.

Over specific investment horizons, the Aarti Drugs share price shows varied returns. The stock delivered a 10-year return of 179.31%. However, it declined 48.7% over five years and 9.36% over three years, highlighting recent challenges. These trends align with cycles in global API demand, competitive intensity, and raw material inflation impacting the sector.

Despite sector disruptions, the Aarti Drugs share price has shown resilience at certain levels. While the broader pharmaceutical sector faced cost and regulatory hurdles, the company’s established client relationships and manufacturing capabilities provided stability. The Aarti Drugs stock price movement is a function of these operational factors within a globally competitive and regulated industry framework.

Aarti Drugs Limited Investor Relevance and Portfolio Role

Aarti Drugs offers exposure to the API and pharmaceutical intermediate segment within healthcare portfolios. Its inclusion in indices like the S&P BSE Healthcare and various small-cap/micro-cap indices underscores its relevance within its specific market capitalisation segment. Factors like backward integration, regulatory approvals, and export market presence make it a stock of interest for investors focused on the pharmaceutical supply chain.

Aarti Drugs equity is held by a mix of domestic institutional investors and funds. Top institutional stakeholders include DSP BlackRock Investment Managers, DSP Asset Managers, Gogri And Sons Investments, Anushakti Enterprise, Alchemie Leasing and Financing, ICICI Prudential Asset Management, Aashyav Business Trust, Unifi Capital, Tulip Family Trust, and Orchid Family Trust.

Prominent mutual fund holders include the DSP Small Cap Fund, ICICI Prudential Pharma Healthcare and Diagnostics Fund, DSP Healthcare Fund, and the Motilal Oswal Nifty Microcap 250 Index Fund. Global funds such as DFA Emerging Markets Core Equity Portfolio, Avantis Emerging Markets Equity ETF, WisdomTree India Earnings Fund, DFA Emerging Markets Small Cap Series, and Dimensional Emerging Markets ETF also hold stakes. This base highlights its role in sector-specific and emerging market portfolios.

Beyond ownership, technical indicators like RSI and MACD provide insight into short-term momentum shifts in the Aarti Drugs stock price. These tools help gauge market sentiment around quarterly results or sector news.

The beta of Aarti Drugs indicates its volatility relative to the market. The long-term beta is 1.54. Over different periods, beta values range from 0.900 on a daily one-month basis to 1.53 on a monthly two-year basis, with a daily three-month beta of 1.13 and a weekly one-year beta of 1.43. These figures, with a mean price around ₹463.37 and standard deviations varying from 1.15 to 11.13 across periods, suggest the Aarti Drugs share price has historically experienced higher volatility than the broader market. This reflects the stock’s sensitivity to sector-specific news and its mid-small cap profile.

Aarti Drugs Limited Sectoral Relevance and Peer Positioning

Aarti Drugs’ sector relevance stems from its position as an integrated API manufacturer, supporting India’s pharmaceutical formulation industry. Peer comparisons with companies like Divi’s Laboratories, Solara Active Pharma Sciences, Granules India, Sudarshan Pharma, and IOL Chemicals and Pharmaceuticals focus on product portfolio, vertical integration, export market diversification, and regulatory compliance rather than short-term stock moves. These benchmarks help assess operational scale, cost leadership, and sustainability within the competitive API sector.

Aarti Drugs’ market cap history shows significant growth and volatility tied to its earnings cycle. The market cap stood at ₹1.02 billion in 2007 before dropping 56.97% to ₹0.44 billion in 2008. A strong recovery followed, reaching ₹1.22 billion in 2009 (up 176.32%) and ₹1.85 billion in 2010 (up 51.79%). After a 50.06% decline to ₹0.92 billion in 2011, it entered a multi-year growth phase, rising to ₹10.32 billion in 2014 (a 279.42% increase) and ₹45.04 billion by 2023. Recent years show moderation, with market cap at ₹41.29 billion in 2024 and ₹38.08 billion in 2025.

Aarti Drugs earnings history reflects its operational performance over business cycles. EBIT grew steadily from ₹1.11 billion in 2013 to ₹1.39 billion in 2014 (up 25.2%). After a slight dip to ₹1.37 billion in 2015, earnings resumed growth, reaching ₹2.00 billion in 2019. A significant surge occurred in 2020, with earnings hitting ₹3.90 billion, a 94.37% increase, driven by pandemic-led demand. Earnings then moderated to ₹2.83 billion in 2021 and ₹2.51 billion in 2022. A recovery to ₹2.77 billion occurred in 2023, before a decrease to ₹2.40 billion in 2024. The TTM earnings for 2025 are ₹2.67 billion.

Aarti Drugs EPS provides a per-share view of profitability. EPS was ₹11.12 in 2016, growing to ₹11.93 in 2017 (a 7.28% increase) and further to ₹12.19 in 2018 (up 2.22%). The latest reported trailing twelve-month (TTM) EPS for 2025 is ₹18.75. This progression in EPS highlights the company’s ability to grow earnings on a per-share basis over time, factoring in its capital structure and operational results.

Aarti Drugs P/E ratio shows how the market has valued its earnings. The P/E ratio was 18.2 at the end of 2016. It increased to 18.5 in 2017, reflecting stable valuation. By the end of 2018, the P/E ratio had decreased to 15.5, a 16.03% drop, indicating a lower market valuation relative to earnings at that time. The current P/E ratio (TTM) as of January 2026 is 18.4, suggesting a valuation comparable to its historical range.

Summary

Aarti Drugs Limited is a listed manufacturer of active pharmaceutical ingredients and intermediates. The Aarti Drugs share price is influenced by sector-specific factors like API demand, regulatory environment, and input costs. The company is represented on various stock indices and has a documented history of earnings, market capitalization, and stock performance, which is tracked by a range of institutional and mutual fund investors.